Clinical Trial Update: Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating adding abemaciclib to olaparib in women with recurrent ovarian cancer, including high-grade serous and platinum-resistant disease; curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Cancer
• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 1 | Status: RECRUITING